Abstract:Understanding biological systems at the level of their relational (emergent) molecular properties in functional protein networks relies on imaging methods, able to spatially resolve a tissue or a cell as a giant, non-random, topologically defined collection of interacting supermolecules executing myriads of subcellular mechanisms. Here, the development and findings of parameter-unlimited functional super-resolution microscopy are described—a technology based on the fluorescence imaging cycler (IC) principle ca… Show more
“…The TIS technology used here, as noted in the Introduction, has advantages over other more recently introduced multiplexing methods [41,51,55,56]. In these systems the antibodies are tagged with Cy dyes and the fluorescence is quenched by exposing the sections to H 2 O 2 at pH > 10.…”
Section: Discussionmentioning
confidence: 99%
“…We opted to use TIS for several reasons. Exposing the sections to H 2 O 2 at pH > 10 to quench the fluorescence [41,51,56,57], unlike photobleaching used in TIS, has been found to alter epitopes of some proteins and may decrease, eliminate, or enhance the fluorescence signal [41,57]. Unlike TIS the newer systems are yet to be automated and importantly lack the capabilities offered by the image processing software developed for use with TIS and referred to above.…”
Section: Discussionmentioning
confidence: 99%
“…Here we applied TIS (or MELC) [36,[41][42][43][44] to use Combinatorial Molecular Phenotypes or CMPs to characterize the heterogeneity of AM. A CMP is a designation indicating the presence or absence of all markers in a given pixel.…”
Section: Introductionmentioning
confidence: 99%
“…In all images there are 2 n possible CMPs where n = the number of markers used. TIS is a high throughput robotically-controlled microscopic system developed by Schubert [36,[41][42][43]. It enables immunophenotyping cells in their native environment by using robotically controlled reiterative cycles of immunostaining (tagging), imaging, and photobleaching of FITC-conjugated antibodies.…”
Background: We used the Toponome Imaging System (TIS) to identify "patterns of marker expression", referred to here as combinatorial molecular phenotypes (CMPs) in alveolar macrophages (AM) in response to the innate immune molecule, SP-A1. Methods: We compared 114 AM from male SPA deficient mice. One group (n = 3) was treated with exogenous human surfactant protein A1 (hSP-A1) and the other with vehicle (n = 3). AM obtained by bronchoalveolar lavage were plated onto slides and analyzed using TIS to study the AM toponome, the spatial network of proteins within intact cells. With TIS, each slide is sequentially immunostained with multiple FITC-conjugated antibodies. Images are analyzed pixel-by-pixel identifying all of the proteins within each pixel, which are then designated as CMPs. CMPs represent organized protein clusters postulated to contribute to specific functions. Results: 1) We compared identical CMPs in KO and SP-A1 cells and found them to differ significantly (p = 0.0007). Similarities between pairs of markers in the two populations also differed significantly (p < 0.0001). 2) Focusing on the 20 most abundant CMPs for each cell, we developed a method to generate CMP "signatures" that characterized various groups of cells. Phenotypes were defined as cells exhibiting similar signatures of CMPs. i) AM were extremely diverse and each group contained cells with multiple phenotypes. ii) Among the 114 AM analyzed, no two cells were identical. iii) However, CMP signatures could distinguish among cell subpopulations within and between groups. iv) Some cell populations were enriched with SP-A1 treatment, some were more common without SP-A1, and some seemed not to be influenced by the presence of SP-A1. v) We also found that AM were more diverse in mice treated with SP-A1 compared to those treated with vehicle. Conclusions: AM diversity is far more extensive than originally thought. The increased diversity of SP-A1-treated mice points to the possibility that SP-A1 enhances or activates several pathways in the AM to better prepare it for its innate immune functions and other functions shown previously to be affected by SPA treatment. Future studies may identify key protein(s) responsible for CMP integrity and consequently for a given function, and target it for therapeutic purposes.
“…The TIS technology used here, as noted in the Introduction, has advantages over other more recently introduced multiplexing methods [41,51,55,56]. In these systems the antibodies are tagged with Cy dyes and the fluorescence is quenched by exposing the sections to H 2 O 2 at pH > 10.…”
Section: Discussionmentioning
confidence: 99%
“…We opted to use TIS for several reasons. Exposing the sections to H 2 O 2 at pH > 10 to quench the fluorescence [41,51,56,57], unlike photobleaching used in TIS, has been found to alter epitopes of some proteins and may decrease, eliminate, or enhance the fluorescence signal [41,57]. Unlike TIS the newer systems are yet to be automated and importantly lack the capabilities offered by the image processing software developed for use with TIS and referred to above.…”
Section: Discussionmentioning
confidence: 99%
“…Here we applied TIS (or MELC) [36,[41][42][43][44] to use Combinatorial Molecular Phenotypes or CMPs to characterize the heterogeneity of AM. A CMP is a designation indicating the presence or absence of all markers in a given pixel.…”
Section: Introductionmentioning
confidence: 99%
“…In all images there are 2 n possible CMPs where n = the number of markers used. TIS is a high throughput robotically-controlled microscopic system developed by Schubert [36,[41][42][43]. It enables immunophenotyping cells in their native environment by using robotically controlled reiterative cycles of immunostaining (tagging), imaging, and photobleaching of FITC-conjugated antibodies.…”
Background: We used the Toponome Imaging System (TIS) to identify "patterns of marker expression", referred to here as combinatorial molecular phenotypes (CMPs) in alveolar macrophages (AM) in response to the innate immune molecule, SP-A1. Methods: We compared 114 AM from male SPA deficient mice. One group (n = 3) was treated with exogenous human surfactant protein A1 (hSP-A1) and the other with vehicle (n = 3). AM obtained by bronchoalveolar lavage were plated onto slides and analyzed using TIS to study the AM toponome, the spatial network of proteins within intact cells. With TIS, each slide is sequentially immunostained with multiple FITC-conjugated antibodies. Images are analyzed pixel-by-pixel identifying all of the proteins within each pixel, which are then designated as CMPs. CMPs represent organized protein clusters postulated to contribute to specific functions. Results: 1) We compared identical CMPs in KO and SP-A1 cells and found them to differ significantly (p = 0.0007). Similarities between pairs of markers in the two populations also differed significantly (p < 0.0001). 2) Focusing on the 20 most abundant CMPs for each cell, we developed a method to generate CMP "signatures" that characterized various groups of cells. Phenotypes were defined as cells exhibiting similar signatures of CMPs. i) AM were extremely diverse and each group contained cells with multiple phenotypes. ii) Among the 114 AM analyzed, no two cells were identical. iii) However, CMP signatures could distinguish among cell subpopulations within and between groups. iv) Some cell populations were enriched with SP-A1 treatment, some were more common without SP-A1, and some seemed not to be influenced by the presence of SP-A1. v) We also found that AM were more diverse in mice treated with SP-A1 compared to those treated with vehicle. Conclusions: AM diversity is far more extensive than originally thought. The increased diversity of SP-A1-treated mice points to the possibility that SP-A1 enhances or activates several pathways in the AM to better prepare it for its innate immune functions and other functions shown previously to be affected by SPA treatment. Future studies may identify key protein(s) responsible for CMP integrity and consequently for a given function, and target it for therapeutic purposes.
“…These spatial blueprints, in turn, typically include so-called emergent systems [10], where emergence is understood as the process of complex pattern formation from more basic constituent parts [10]: large combinatorial molecular structures acquire, e.g. through the differential interplay of the numerous different protein classes, new properties in health and disease [10].…”
This article deals with a molecular geometry imaging platform capable of mapping the spatial protein-colocalisation and anti-colocalisation code of large molecular systems at a time. The platform called molecular unlimited systems imaging cycler (MUSIC) robotics was applied to amyotrophic lateral sclerosis (ALS). The detection of ALS specific cells with a corresponding multimolecular geometry in the blood led to therapeutic depletion of these cells and to recovery of the treated patient, obviously because this therapy interferes with pathogenic invasion of these cells into the central nervous system, where they axotomize motor axons. Large scale geometry MUSIC robotics imaging of up to 4.5 × 10 481 power of combinatorial molecular resolution is key to detect these cells and to control depletion therapy for clinical success. These data and new possibilities may argue for clinical application and for a systematic research in the field of molecular geometry of diseases to discover new mathematically defined insight.
An imaging cycler microscope (ICM) is a fully automated (epi)fluorescence microscope which overcomes the spectral resolution limit resulting in parameter-and dimensionunlimited fluorescence imaging. This enables the spatial resolution of large molecular systems with their emergent topological properties (toponome) in morphologically intact cells and tissues displaying thousands of multi protein assemblies at a time. The resulting combinatorial geometry of these systems has been shown to be key for invivo/in-situ detection of lead proteins controlling protein network topology and (dys)-function: If lead proteins are blocked or downregulated the corresponding disease protein network disassembles. Here, correct therapeutic predictions are exemplified for ALS. ICM drug target studies have discovered an 18-dimensional cell surface molecular system in ALS-PBMC with a lead drug target protein, whose therapeutic downregulation is now reported to show statistically significant effect with stop of disease progression in one third of the ALS patients. Together, this clinical and the earlier experimental validations of the ICM approach indicate that ICM readily discovers in vivo robustness nodes of disease with lead proteins controlling them. Breaking in vivo robustness nodes using drugs against their lead proteins is likely to overcome current high drug attrition rates. V C 2015 The Author. Published by Wiley Periodicals, Inc, on behalf of ISAC.This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.